Kyron.bio

Kyron.bio is an early-stage, Paris-based biotech focused on engineering the glycosylation of therapeutic proteins to unlock superior drug properties. The company has developed a novel cell line engineering and structure-guided design platform to precisely control N-glycan patterns, aiming to overcome key challenges in antibody therapeutics such as immunogenicity and pharmacokinetics. Backed by a €5.5M seed round and strategic partnerships, Kyron.bio is building its team and advancing its platform towards preclinical development from its base at the Paris Biotech Santé incubator.

Proprietary glycan-engineering platform combining cell line engineering and structure-guided design to precision-control N-glycosylation patterns on therapeutic proteins, particularly antibodies, to optimize their therapeutic properties.

Kyron.bio competes in the broader field of protein and antibody engineering, which includes large biotech firms with internal engineering capabilities and smaller biotechs focused on specific modification technologies (e.g., Fc engineering, bispecifics). Direct competitors include other glycoengineering specialists like GlycoEra, GLYcoDiag, and the glycan-focused research of larger companies. Differentiation hinges on the precision, novelty, and therapeutic impact of its specific engineering approach.